Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cemiplimab + Cisplatin + Paclitaxel |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung squamous cell carcinoma | sensitive | Cemiplimab + Cisplatin + Paclitaxel | Guideline | Actionable | Combination Platinol (cisplatin), Taxol (paclitaxel), and Libtayo (cemiplimab) is in guidelines as first-line therapy for patients with advanced or metastatic squamous cell lung cancer with CD274 (PD-L1) expression of 1% or more, and negative for actionable molecular biomarkers (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |